NEW YORK (AP) _ Intra-Cellular Therapies Inc. (ITCI) on Wednesday reported a loss of $22.9 million in its third quarter.
On a per-share basis, the New York-based company said it had a loss of 53 cents.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 58 cents per share.
The biopharmaceutical company posted revenue of $30,754 in the period. Its adjusted revenue was $31,000.
Intra-Cellular shares have decreased 3 percent since the beginning of the year. The stock has climbed 21 percent in the last 12 months.